Key facts
- IppocraTech’s last known valuation is $9.5M (Apr 2023).
- It has raised $6.9M; the latest was Later Stage VC ($3.1M) in Jan 2025.
- Notable investors include ENEA Tech Biomedical, Fintech Partners, Intesa Sanpaolo, Marzotto Venture Accelerator, Up2Stars.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for IppocraTech
- ·The full record, as it builds
Funding rounds
No funding rounds for IppocraTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About IppocraTech
Developer of a remote patient monitoring device designed to track the vital signs of individuals with chronic health conditions. The company's technology allows medical professionals and individuals to monitor vitals like blood pressure, heart rate, and oxygen saturation remotely, enabling patients to assess their health.
- Sector
- Healthcare
- HQ
- Modena, Italy
- Founded
- 2017
- Employees
- 7
- Website
- ippocra.tech/
- Ownership
- Privately Held (backing)
IppocraTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IppocraTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IppocraTech in its N-PORT filings yet. We sweep new filings monthly.